Jefferies Upgrades Aurinia Pharmaceuticals to Buy, Raises Target to $21
Jefferies upgrades Aurinia Pharmaceuticals to Buy, boosting the price target to $21 on strong Lupkynis sales and promising pipeline prospects.
/ 1676 items
#XY↓
FDA Extends Review for Rhythm’s Obesity Drug Imcivree to March 2026
Rhythm Pharmaceuticals announced that the FDA has extended the review of its obesity drug Imcivree for acquired hypothalamic obesity by three months, moving the decision date to March 20, 2026.
Intellia Therapeutics Shares Plunge 29% After FDA Pauses Key Gene Therapy Trials
Intellia Therapeutics (NTLA) shares fell 29% premarket after the FDA paused two late-stage gene-editing trials following a patient death linked to liver complications.
FIGS Q3: Record Growth and Raised Outlook
FIGS, the healthcare apparel leader, announced exceptional Q3 2025 financial results, showing 8.2% revenue growth, improved profitability, and a boosted full-year outlook.
Novo Nordisk Raises Bid Again for Metsera as Takeover Battle with Pfizer Heats Up
Novo Nordisk boosts its offer for obesity startup Metsera, countering Pfizer’s $86.20 per share bid. The bidding war is nearing its end as both pharma giants race to dominate the booming obesity drug market.
Wolfe Research Starts Coverage on Abivax with Outperform Rating and $176 Target
Wolfe Research initiates coverage of Abivax with an Outperform rating and $176 price target, citing strong potential for Crohn’s disease success and upcoming 2026 catalyst.